Barnaby Young

List of Publications by Year
in descending order

98 papers	10,044 citations	70961 41 h-index	42291 92 g-index
109 all docs	109 docs citations	109 times ranked	20909 citing authors

#	Article	IF	Citations
1	Global haemostatic tests demonstrate the absence of parameters of hypercoagulability in non-hypoxic mild COVID-19 patients: a prospective matched study. Journal of Thrombosis and Thrombolysis, 2022, 53, 646-662.	1.0	11
2	Robust Virus-Specific Adaptive Immunity in COVID-19 Patients with SARS-CoV-2 Î”382 Variant Infection. Journal of Clinical Immunology, 2022, 42, 214-229.	2.0	15
3	Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study. Clinical Microbiology and Infection, 2022, 28, 612.e1-612.e7.	2.8	231
4	Finger stick blood test to assess postvaccination <scp>SARSâ€CoV</scp>â€2 neutralizing antibody response against variants. Bioengineering and Translational Medicine, 2022, 7, .	3.9	7
5	External validation of the PRIORITY model in predicting COVID-19 critical illness in vaccinated and unvaccinated patients. Clinical Microbiology and Infection, 2022, 28, 884.e1-884.e3.	2.8	4
6	Hypercoagulability, endotheliopathy, and inflammation approximating 1â€‰year after recovery: Assessing the longâ€term outcomes in <scp>COVID</scp>â€19 patients. American Journal of Hematology, 2022, 97, 915-923.	2.0	42
7	Sustaining Antimicrobial Stewardship in a Highâ€“Antibiotic Resistance Setting. JAMA Network Open, 2022, 5, e2210180.	2.8	4
8	Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia. Journal of Experimental Medicine, 2022, 219, .	4.2	59
9	Viral Dynamics and Immune Correlates of Coronavirus Disease 2019 (COVID-19) Severity. Clinical Infectious Diseases, 2021, 73, e2932-e2942.	2.9	143
10	The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e48-e51.	1.4	61
11	The place for remdesivir in COVID-19 treatment. Lancet Infectious Diseases, The, 2021, 21, 20-21.	4.6	91
12	Stroke as a Neurological Complication of COVID-19: A Systematic Review and Meta-Analysis of Incidence, Outcomes and Predictors. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105549.	0.7	77
13	COVID-19 associated coagulopathy in critically ill patients: A hypercoagulable state demonstrated by parameters of haemostasis and clot waveform analysis. Journal of Thrombosis and Thrombolysis, 2021, 51, 663-674.	1.0	49
14	Identifying COVID-19 cases in outpatient settings. Epidemiology and Infection, 2021, 149, e92.	1.0	1
15	Human neutralising antibodies elicited by SARSâ€CoVâ€2 nonâ€D614G variants offer crossâ€protection against the SARSâ€CoVâ€2 D614G variant. Clinical and Translational Immunology, 2021, 10, e1241.	1.7	18
16	Sensitive detection of total anti-Spike antibodies and isotype switching in asymptomatic and symptomatic individuals with COVID-19. Cell Reports Medicine, 2021, 2, 100193.	3.3	37
17	Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Reports, 2021, 34, 108728.	2.9	568
18	Diagnostic performance of COVIDâ€19 serological assays during early infection: A systematic review and metaâ€analysis of 11Â516 samples. Influenza and Other Respiratory Viruses, 2021, 15, 529-538.	1.5	17

#	Article	IF	Citations
19	Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation. ELife, 2021, 10, .	2.8	113
20	Association of SARS-CoV-2 clades with clinical, inflammatory and virologic outcomes: An observational study. EBioMedicine, 2021, 66, 103319.	2.7	21
21	Persistent Symptoms and Association With Inflammatory Cytokine Signatures in Recovered Coronavirus Disease 2019 Patients. Open Forum Infectious Diseases, 2021, 8, ofab156.	0.4	77
22	Clinical features and predictors of severity in COVID-19 patients with critical illness in Singapore. Scientific Reports, 2021, 11, 7477.	1.6	16
23	Reply to Letter to Editor. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105881.	0.7	0
24	Asymptomatic COVIDâ€19: disease tolerance with efficient antiâ€viral immunity against SARSâ€CoVâ€2. EMBO Molecular Medicine, 2021, 13, e14045.	3.3	36
25	Predictors for development of critical illness amongst older adults with COVID-19: Beyond age to age-associated factors. Archives of Gerontology and Geriatrics, 2021, 94, 104331.	1.4	27
26	A Virus-Specific Immune Rheostat in the Immunome of Patients Recovering From Mild COVID-19. Frontiers in Immunology, 2021, 12, 674279.	2.2	5
27	Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe, The, 2021, 2, e240-e249.	3.4	322
28	The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody. PLoS ONE, 2021, 16, e0253487.	1.1	76
29	Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors. New England Journal of Medicine, 2021, 385, 1401-1406.	13.9	161
30	Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC Î²-Lactamaseâ€“Producing Enterobacter spp, Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens: A Pilot Multicenter Randomized Controlled Trial (MERINO-2). Open Forum Infectious Diseases, 2021, 8, ofab387.	0.4	42
31	Lack of detail in population-level data impedes analysis of SARS-CoV-2 variants of concern and clinical outcomes. Lancet Infectious Diseases, The, 2021, 21, 1195-1197.	4.6	29
32	Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals. Journal of Clinical Investigation, 2021, 131, .	3.9	89
33	Lack of latent tuberculosis (TB) screening and delay in anti-retroviral therapy initiation in HIV-TB co-infection: an 11-year study in an intermediate TB-burden country. International Journal of Infectious Diseases, 2021, 113, 178-183.	1.5	4
34	Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians. The Lancet Regional Health - Western Pacific, 2021, 15, 100276.	1.3	22
35	Risk Factors for Development of Acute Kidney Injury in COVID-19 Patients: A Retrospective Observational Cohort Study. Nephron, 2021, 145, 256-264.	0.9	27
36	High-risk chest radiographic features associated with COVID-19 disease severity. PLoS ONE, 2021, 16, e0245518.	1.1	9

#	Article	IF	Citations
37	Differentiating coronavirus disease 2019 (COVID-19) from influenza and dengue. Scientific Reports, 2021, 11, 19713.	1.6	15
38	Data-Driven Analysis of COVID-19 Reveals Persistent Immune Abnormalities in Convalescent Severe Individuals. Frontiers in Immunology, 2021, 12, 710217.	2.2	8
39	Oral vs Intravenous Antibiotics for Patients With Klebsiella pneumoniae Liver Abscess: A Randomized, Controlled Noninferiority Study. Clinical Infectious Diseases, 2020, 71, 952-959.	2.9	26
40	Passive immune therapy and other immunomodulatory agents for the treatment of severe influenza: Systematic review and metaâ€analysis. Influenza and Other Respiratory Viruses, 2020, 14, 226-236.	1.5	8
41	Effective Antimicrobial StewaRdship StrategIES (ARIES): Cluster Randomized Trial of Computerized Decision Support System and Prospective Review and Feedback. Open Forum Infectious Diseases, 2020, 7, ofaa254.	0.4	5
42	Whole blood immunophenotyping uncovers immature neutrophil-to-VD2 T-cell ratio as an early marker for severe COVID-19. Nature Communications, 2020, 11, 5243.	5.8	138
43	Acute Onset of Bilateral Follicular Conjunctivitis in two Patients with Confirmed SARS-CoV-2 Infections. Ocular Immunology and Inflammation, 2020, 28, 1280-1284.	1.0	13
44	Statin use is associated with lower disease severity in COVID-19 infection. Scientific Reports, 2020, 10, 17458.	1.6	93
45	Clinical utility of chest radiography for severe COVID-19. Quantitative Imaging in Medicine and Surgery, 2020, 10, 1540-1550.	1.1	36
46	Reversible platypnea-orthodeoxia in COVID-19 acute respiratory distress syndrome survivors. Respiratory Physiology and Neurobiology, 2020, 282, 103515.	0.7	30
47	A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2â€“spike proteinâ€“protein interaction. Nature Biotechnology, 2020, 38, 1073-1078.	9.4	1,042
48	Linear B-cell epitopes in the spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and disease severity. EBioMedicine, 2020, 58, 102911.	2.7	120
49	Safety and potential efficacy of cyclooxygenaseâ€2 inhibitors in coronavirus disease 2019. Clinical and Translational Immunology, 2020, 9, e1159.	1.7	19
50	Associations of viral ribonucleic acid (RNA) shedding patterns with clinical illness and immune responses in Severe Acute Respiratory Syndrome Coronavirus 2 (SARSâ€CoVâ€2) infection. Clinical and Translational Immunology, 2020, 9, e1160.	1.7	31
51	Fever Patterns, Cytokine Profiles, and Outcomes in COVID-19. Open Forum Infectious Diseases, 2020, 7, ofaa375.	0.4	33
52	Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study. Lancet, The, 2020, 396, 603-611.	6.3	394
53	Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2. Emerging Microbes and Infections, 2020, 9, 900-902.	3.0	89
54	Risk Factors for Severe Disease and Efficacy of Treatment in Patients Infected With COVID-19: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis. Clinical Infectious Diseases, 2020, 71, 2199-2206.	2.9	227

#	Article	IF	Citations
55	Reply. Ophthalmology, 2020, 127, e104-e105.	2.5	2
56	Serological differentiation between COVID-19 and SARS infections. Emerging Microbes and Infections, 2020, 9, 1497-1505.	3.0	89
57	Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures. Lancet, The, 2020, 395, 1039-1046.	6.3	561
58	SARS-CoV-2 Infection among Travelers Returning from Wuhan, China. New England Journal of Medicine, 2020, 382, 1476-1478.	13.9	111
59	COVID-19 in gastroenterology: a clinical perspective. Gut, 2020, 69, 1144-1145.	6.1	96
60	Epidemiological and Clinical Predictors of COVID-19. Clinical Infectious Diseases, 2020, 71, 786-792.	2.9	181
61	Assessing Viral Shedding and Infectivity of Tears in Coronavirus Disease 2019 (COVID-19) Patients. Ophthalmology, 2020, 127, 977-979.	2.5	317
62	Absence of contamination of personal protective equipment (PPE) by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Infection Control and Hospital Epidemiology, 2020, 41, 614-616.	1.0	59
63	Clinical course and physiotherapy intervention in 9 patients with COVID-19. Physiotherapy, 2020, 109, 1-3.	0.2	16
64	Metagenome-wide association analysis identifies microbial determinants of post-antibiotic ecological recovery in the gut. Nature Ecology and Evolution, 2020, 4, 1256-1267.	3.4	98
65	Influenza in temperate and tropical Asia: a review of epidemiology and vaccinology. Human Vaccines and Immunotherapeutics, 2020, 16, 1659-1667.	1.4	22
66	Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA - Journal of the American Medical Association, 2020, 323, 1488.	3.8	1,700
67	Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal Î²-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia. JAMA - Journal of the American Medical Association, 2020, 323, 527.	3.8	169
68	Blood and blood product use during <scp>COVID</scp>â€19 infection. American Journal of Hematology, 2020, 95, E158-E160.	2.0	41
69	Care of the pregnant woman with coronavirus disease 2019 in labor and delivery: anesthesia, emergencyÂcesarean delivery, differential diagnosisÂinÂtheÂacutely ill parturient, care of the newborn,Âand protection of the healthcare personnel. American Journal of Obstetrics and Gynecology, 2020, 223, 66-74.e3.	0.7	104
70	Testing for SARS-CoV-2: Can We Stop at 2?. Clinical Infectious Diseases, 2020, 71, 2246-2248.	2.9	52
71	Influenza vaccine failure in the tropics: a retrospective cohort study of waning effectiveness. Epidemiology and Infection, 2020, 148, e299.	1.0	10
72	Variable computed tomography appearances of COVID-19. Singapore Medical Journal, 2020, 61, 387-391.	0.3	12

#	Article	IF	Citations
73	Pregnancy Outcomes in COVID-19: A Prospective Cohort Study in Singapore. Annals of the Academy of Medicine, Singapore, 2020, 49, 857-869.	0.2	15
74	Hybrid metagenomic assembly enables high-resolution analysis of resistance determinants and mobile elements in human microbiomes. Nature Biotechnology, 2019, 37, 937-944.	9.4	216
75	Rapidly waning vaccine effectiveness for influenza: How often should we revaccinate?. Journal of Travel Medicine, 2019, 26, .	1.4	2
76	Semiannual Versus Annual Influenza Vaccination in Older Adults in the Tropics: An Observer-blind, Active-comparatorâ€“controlled, Randomized Superiority Trial. Clinical Infectious Diseases, 2019, 69, 121-129.	2.9	14
77	Duration of Influenza Vaccine Effectiveness: A Systematic Review, Meta-analysis, and Meta-regression of Test-Negative Design Case-Control Studies. Journal of Infectious Diseases, 2018, 217, 731-741.	1.9	105
78	Influenza on cruise ships. Journal of Travel Medicine, 2018, 25, .	1.4	7
79	186. Effective Antimicrobial StewaRdship StrategIES (ARIES): Cluster-Randomized Trial of a Clinical Decision Support System to Supplement Antibiotic Prospective Review and Feedback. Open Forum Infectious Diseases, 2018, 5, S82-S83.	0.4	0
80	Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance. JAMA - Journal of the American Medical Association, 2018, 320, 984.	3.8	538
81	Clinical impact of non-antibiotic recommendations by a multi-disciplinary antimicrobial stewardship team. International Journal of Antimicrobial Agents, 2017, 50, 166-170.	1.1	8
82	Clinical and Molecular Epidemiology of Carbapenem-Resistant Enterobacteriaceae Among Adult Inpatients in Singapore. Clinical Infectious Diseases, 2017, 64, S68-S75.	2.9	62
83	Do antibody responses to the influenza vaccine persist year-round in the elderly? A systematic review and meta-analysis. Vaccine, 2017, 35, 212-221.	1.7	78
84	Epidemiology and Relative Severity of Influenza Subtypes in Singapore in the Post-Pandemic Period from 2009 to 2010. Clinical Infectious Diseases, 2017, 65, 1905-1913.	2.9	17
85	The immune response to 6-monthly versus annual standard dose inactivated trivalent influenza vaccination in older people: study protocol for a randomised clinical trial. Trials, 2017, 18, 67.	0.7	4
86	PostoperativeMycoplasma hominisbrain abscess: keep it in mind!. BMJ Case Reports, 2017, 2017, bcr2016218022.	0.2	9
87	The Uncertain Benefits of Combination Therapy forClostridium difficileInfection. Clinical Infectious Diseases, 2016, 62, 809.1-810.	2.9	3
88	The avian influenza vaccine Emerflu. Why did it fail?. Expert Review of Vaccines, 2015, 14, 1125-1134.	2.0	15
89	Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infectious Diseases, The, 2015, 15, 793-802.	4.6	104
90	Derivation and validation of an accurate estimation of CD4 counts from the absolute lymphocyte count in virologically suppressed and immunologically reconstituted HIV infected adults. BMC Infectious Diseases, 2015, 15, 330.	1.3	2

#	Article	IF	Citations
91	The absolute lymphocyte count accurately estimates CD4 counts in HIVâ€infected adults with virologic suppression and immune reconstitution. Journal of the International AIDS Society, 2014, 17, 19680.	1.2	2
92	Improved outcomes from HIV/TB co-infection in Singapore following a switch to earlier anti-retroviral therapy. Journal of the International AIDS Society, 2014, 17, 19624.	1.2	0
93	A prospective observational study of the prevalence and risk factors for colonization by antibiotic resistant bacteria in patients at admission to hospital in Singapore. BMC Infectious Diseases, 2014, 14, 298.	1.3	39
94	Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet, The, 2014, 383, 1474-1482.	6.3	144
95	Whatâ€²s new in critical illness and injury science? Preventing surgical infections requires the right antibiotic for the right duration. International Journal of Critical Illness and Injury Science, 2012, 2, 55.	0.2	0
96	Infectious disease trends among immunocompromised hosts. Singapore Medical Journal, 2012, 53, 223-9; quiz 230.	0.3	1
97	Progressive Multifocal Leukoencephalopathy with Immune Reconstitution Inflammatory Syndrome (PML-IRIS): two case reports of successful treatment with mefloquine and a review of the literature. Annals of the Academy of Medicine, Singapore, 2012, 41, 620-4.	0.2	1
98	Nonconcordance with Surgical Site Infection Prevention Guidelines and Rates of Surgical Site Infections for General Surgical, Neurological, and Orthopedic Procedures. Antimicrobial Agents and Chemotherapy, 2011, 55, 4659-4663.	1.4	50